Thursday, September 1, 2022

Agios up on Forma deal

 

Agios Pharmaceuticals (NASDAQ:AGIO), a biotech targeting the blood disorder sickle cell disease (SCD), climbed after news of Novo deal for Forma.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.